Roux-en-Y Gastric Bypass: The Old Standard Still Holding On
The older weight-loss operation keeps winning trials against the sleeve while serving mostly as the place sleeve patients end up next.

Today one of the more reliable ways to end up with a Roux-en-Y gastric bypass is to first get a different operation. The bypass is the older of the two big weight-loss surgeries. It has spent years losing the popularity contest to the gastric sleeve while doing quite well in the head-to-head trials, and it also runs a steady side business as the place sleeve patients go next.
The plain version: the surgeon makes a small pouch out of the top of the stomach and connects it to the small intestine farther down, so food skips most of the stomach and the duodenum (the first stretch of intestine). In the best randomized comparison against the sleeve, the bypass produced more weight loss, more diabetes remission and much less acid reflux. In exchange, patients got more low blood sugar after meals and a gut that now handles food in an unusual order. Whether that trade is worth it depends on who is making it, and the evidence for that is less complete than anyone would like.
What a Roux-en-Y bypass is, and why it stopped being the default
The “Y” is literal. Two limbs of intestine meet at a junction, and the result looks, on a diagram, like the letter. Food travels down one arm, digestive juices come down the other, and they meet later than nature planned. It is plumbing, in some sense, and the plumbing is the point.
It used to be the default operation. Now it is not. A seven-year study of revision operations after the sleeve opens with the sentence “Sleeve gastrectomy is currently the most performed bariatric procedure worldwide,” and “performed” is doing a lot of work there. The sleeve is the one with the bookings. The bypass is the one with the reviews.
(I spend my working hours reading confidence intervals for a website, which is a job that sounds better at parties than it is.)
What the Oseberg trial says the bypass buys
The cleanest evidence here comes from the Oseberg trial in Norway. It enrolled 109 people with type 2 diabetes between October 15, 2012, and September 1, 2017, and randomly assigned 54 to gastric bypass and 55 to sleeve gastrectomy. It was triple-blind, which means the patients did not know which operation they got. You can have abdominal surgery and not know which one. Medicine is strange.
At five years, 63% of the bypass group had diabetes remission (an HbA1c under 6.5%), versus 30% of the sleeve group. So the bypass is basically twice as good at diabetes. Actually, no. The trial reports a risk difference of 33.5 percentage points with a confidence interval running from 14.1 to 52.9, which is a more precise and much odder statement: the true advantage could be modest, or it could be more than half the room. It is a big advantage. It is just a blurry one.
The one-year results pointed the same way (a risk ratio of 1.57, p=0.0054, in the intention-to-treat analysis). On weight, the bypass group had lost 22.2% of body weight at five years versus 17.2% for the sleeve. That is a five-point gap, which in a trial table is a small number and on an actual person is a fair amount of person. No one died in either group.
There is also a stranger finding, from a separate long-term study reported through the American College of Surgeons. Bypass patients who regained 100% or more of the weight they had lost still kept their diabetes in remission in about 60% of cases. I mean, that is the operation continuing to work on a problem after appearing to fail at the other one. The researchers read it as a “weight-independent metabolic benefit from duodenal bypass,” which is a formal way of saying the rerouting matters on its own.
There is a meta-analysis of 24 randomized trials and 2,890 participants comparing the two operations on cardiometabolic outcomes. Its headline numbers are not in the material gathered here, so I won’t guess at them.
The sleeve’s customers, and where they end up
Here is the chain. The sleeve is simpler and has become the most common operation. The sleeve also causes reflux: in Oseberg, pathological acid reflux was more common after the sleeve by 51.1 percentage points. Some sleeve patients reflux, or regain, and need something else. The something else is very often a bypass.
How often? In one German randomized trial of sleeves with and without a band, 20% of standard sleeve patients had been converted to gastric bypass by five years. In a Polish ten-year study, BARI-10-POL, 24.3% of sleeve patients needed a revision. So the bypass’s best-selling product line is, in some sense, fixing the sleeve.
The obvious next move is to make the sleeve fail less. That German trial wrapped a band around some sleeves, and the conversion rate fell to 11.9%. Postprandial regurgitation rose from 23% to 59%. It’s fine. Every fix gets paid for with something.
Then the bypass has its own failures. A Spanish trial protocol comparing bypass with SADI-S puts it bluntly: the bypass is “associated with suboptimal response or recurrent weight gain” in 25% to 50% of cases. So the patients who left the sleeve for the bypass can now leave the bypass for a stronger operation, or for a drug: the BARI-STEP trial enrolled people at least a year after bypass or sleeve with “a suboptimal clinical response” and gave them semaglutide or placebo. Each link in this chain is, I assume, billed by someone, and each is a reasonable answer to the link before it. Laid end to end, they describe a patient who has had two operations and is now in a drug trial.
Someone also looked at the bypass and decided, in the spirit of Beyoncé, that if you liked it you should have put a ring on it. Ring-augmented bypass has been tested in five randomized trials with 920 patients. The ring bought a little more excess weight loss at one, two and three years (about 3 to 4 points), no clear difference at five years in a sample of only 173 patients, roughly three times as much vomiting, and an early signal of more reoperations. Picture the planning meeting (made up, obviously): “Great news, the ring works. Mostly in the vomiting department.” Lol.
What the bypass costs the body
The best-measured cost is hypoglycemia. In Oseberg, symptomatic low blood sugar after meals hit 28% of bypass patients versus 2% of sleeve patients. That is the same rerouting that helps diabetes, doing too much of its job at the wrong moment.
Oseberg also counted 10 early complications among 54 bypass patients and late side effects in 17 of 53. The denominator dropped by one between those two figures, and the source does not say why. A separate study of tummy-tuck surgery after massive weight loss found bypass patients had the highest major complication rate, 39.1%, but that was a subgroup of 23 people, which is small enough that I wouldn’t hang much on it.
The long-run vitamin and mineral picture is the part people usually mean by the nutritional consequences of a bypass. The sources gathered for this piece do not put numbers on it, so this piece will not pretend to. That question is not settled here.
When the bypass beats the sleeve, and what is not settled
On the randomized evidence collected here, the bypass beats the sleeve on diabetes remission, on weight loss, and quite clearly on reflux. It loses on post-meal hypoglycemia. A newer hybrid, SASI bypass, shows a similar trade against the sleeve in a meta-analysis of 13 studies: better diabetes remission (an odds ratio of 4.20) and better reflux remission, alongside a higher overall complication rate (an odds ratio of 4.39).
What is not settled: one long-term review puts ten-year total weight loss anywhere from 24.4% for the sleeve to about 40% for duodenal switch, but the bypass’s own ten-year figure is not in these facts. Oseberg was a single center with 109 people. How the bypass compares with the newer drugs is a different question, and other articles on this site deal with it. I don’t know who should get which operation, and neither, on these numbers, does anyone else with great precision.
The bypass is no longer the first choice. It is often the second one.
Sources
- Roux-en-Y Gastric Bypass versus Sleeve Gastrectomy for Cardiometabolic Outcomes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
- A randomized open-label multicentre clinical trial comparing single-anastomosis duodenal switch (SADI-S) versus Roux-en-Y gastric bypass for the treatment of severe obesity: BYPSADIS study protocol
- Banded Versus Non-banded Sleeve Gastrectomy: 5-Year Results of a 3-Year Randomized Controlled Trial
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
- Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
- Scholars@Duke publication: Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.
- Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Gastric Bypass Improves Long-Term Diabetes Remission, Even After Weight Recurrence | ACS
- Continued Diabetes Remission Despite Weight Recurrence: Gastric Bypass Long-Term Metabolic Benefit.
- A Comparative Outcome Review of Abdominoplasty Following Massive Weight Loss
- GERD remission and safety profile of Single Anastomosis Sleeve Ileal (SASI) bypass vs sleeve gastrectomy (SG): a systematic review and meta-analysis
- Long-term outcomes of metabolic bariatric surgery: a 10-Year multicenter retrospective study in Poland (BARI-10-POL)
- Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
- Ring-Augmented Versus Standard Roux-en-Y Gastric Bypass: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment
- A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.